Jyong Biotech Ltd. is a Taiwan-based clinical-stage biotechnology company developing drug candidates for cancer and other diseases, with its primary focus on advancing Botreso®, an advanced botanical drug candidate in clinical trials for various cancers, alongside other clinical-stage candidates in its pipeline. The company currently generates no revenue from product sales and finances operations through bank loans while incurring ongoing net losses, with future revenues dependent on obtaining regulatory approvals from the Taiwan FDA, U.S. FDA, and other foreign authorities and successfully commercializing its candidates through established manufacturing and commercialization infrastructure. The company faces material financial liabilities from failed pharmaceutical factory development projects in China that substantially exceed originally anticipated amounts and may constrain available capital for research and development activities.